<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Calcium channel blockers in the management of chronic coronary syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Calcium channel blockers in the management of chronic coronary syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Calcium channel blockers in the management of chronic coronary syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph P Kannam, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Calcium channel blockers are a heterogeneous group of compounds used in a variety of cardiovascular disorders such as stable angina pectoris, vasospastic angina, hypertension, hypertrophic cardiomyopathy, and supraventricular arrhythmias.
        </p>
        <p>
         This topic review will present the major issues regarding the use of calcium channel blockers in the patient with stable angina and the evidence that these drugs are effective. Their role, compared with other drugs, in the overall management of chronic coronary syndrome is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1483.html" rel="external">
          "Chronic coronary syndrome: Overview of care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          MECHANISM OF ACTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Calcium influx into the myocyte initiates a series of events essential for contractility. Calcium entry into the myocyte first triggers intracellular calcium release; the released calcium then binds the regulatory protein troponin, resulting in a calcium-troponin complex which allows actin and myosin to interact and contract. The sequence of events is the same in vascular smooth muscle cells, except that a calcium-calmodulin complex instead of calcium-troponin permits the interaction between actin and myosin. The net effect is vasodilatation; the ensuing fall in blood pressure decreases cardiac work and may contribute to the efficacy of these drugs in the patient with angina.
        </p>
        <p>
         Calcium channel blockers work by blocking the initial calcium influx into myocytes and vascular smooth muscle cells, preventing the cascade of events detailed above. The available calcium channel blocking agents block receptors on the L-type calcium channel which gives rise to a slowly inactivating high threshold current in cardiac cells.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CARDIOVASCULAR AND ADVERSE SIDE EFFECTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The currently available calcium channel blockers may be categorized into three groups based upon different chemical structures:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The dihydropyridines (
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">
          amlodipine
         </a>
         , and others)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          Verapamil
         </a>
         , which is structurally similar to
         <a class="drug drug_general" data-topicid="9739" href="/z/d/drug information/9739.html" rel="external">
          papaverine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          Diltiazem
         </a>
         , a benzothiazepine derivative
        </p>
        <p>
        </p>
        <p>
         These classes have varying mechanisms of action, leading to different effects on cardiovascular function and different types of side effects.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Dihydropyridines
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dihydropyridines have the following actions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They block slow calcium channels in a dose-dependent fashion [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They have a greater selectivity for vascular smooth muscle than for the myocardium, making them more potent vasodilators than either
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         or
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They vasodilate coronary arteries, reduce coronary resistance, increase coronary blood flow, and may enhance the development of coronary collaterals [
         <a href="#rid3">
          3,4
         </a>
         ]. The vasodilatation and increase in coronary artery blood flow result from the blockade of calcium influx as well as an increase the levels of nitric oxide and bradykinin; therefore, the increase in coronary artery blood flow is a result of bradykinin/nitric oxide-dependent and -independent mechanisms [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They elicit a strong reflex beta-adrenergic response, making any potential negative inotropic or chronotropic effect clinically insignificant. This adrenergic response often includes a reflex tachycardia [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         These actions determine the side effect profile of the dihydropyridines and the clinical settings in which they should or should not be used. Short-acting
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         has a relatively high incidence of adverse side effects, including peripheral edema (not related to heart failure), flushing, headaches, and lightheadedness, all caused by peripheral vasodilatation. (See
         <a class="medical medical_review" href="/z/d/html/3832.html" rel="external">
          "Major side effects and safety of calcium channel blockers"
         </a>
         .) These symptoms are less common with long-acting nifedipine or second generation dihydropyridines such as
         <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">
          amlodipine
         </a>
         and
         <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">
          nicardipine
         </a>
         .
        </p>
        <p>
         There are several potential problems that must be considered when using a dihydropyridine in a patient with angina.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          Nifedipine
         </a>
         may exacerbate ischemia in some patients by causing a reflex tachycardia, preventing its use in patients with unstable angina or myocardial infarction (MI).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is only a mild negative inotropic effect, but these agents should be used with caution in patients with severe myocardial depression.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Verapamil
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          Verapamil
         </a>
         has different physiologic effects from the dihydropyridines because of a different interaction with the calcium channels. Verapamil is effective in angina because it decreases myocardial oxygen demand by acting as a negative inotrope and chronotrope and by lowering the systemic blood pressure. Changes in contractility are minimal in patients without heart disease; however, verapamil can exacerbate heart failure in patients with cardiac dysfunction due to its negative inotropic activity. This effect is more pronounced in patients who are also treated with a beta blocker, a combination that is not generally used. Verapamil also slows cardiac conduction, an effect that may be deleterious in patients with sinus node dysfunction or atrioventricular block.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          Verapamil
         </a>
         is much less potent vasodilator than the dihydropyridines. As a result, side effects such as headache, flushing, peripheral edema, and lightheadedness are less common. It should be avoided in patients with a left ventricular ejection fraction less than 40 percent.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Diltiazem
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          Diltiazem
         </a>
         has actions that fall between the dihydropyridines and
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          Diltiazem
         </a>
         is a potent coronary but a mild arterial vasodilator, producing improved blood flow through coronary epicardial vessels, collaterals, and normal and ischemic myocardium, as well as lowering mean arterial pressure [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It may depress sinus node automaticity and AV nodal conduction time but this effect is less prominent than that seen with
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          Diltiazem
         </a>
         is a negative inotrope.
        </p>
        <p>
        </p>
        <p>
         The net effect is that
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         may be somewhat better tolerated than the other calcium channel blockers, since it is neither a potent vasodilator nor a myocardial depressant.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          EFFECTIVENESS
         </span>
         <span class="headingEndMark">
          —
         </span>
         All calcium channel blockers are effective in the treatment of stable angina pectoris [
         <a href="#rid9">
          9
         </a>
         ]. However, short-acting
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         is limited by reflex tachycardia which may exacerbate ischemia, thereby preventing its use as monotherapy in this disorder. It should be avoided in patients with a left ventricular ejection fraction less than 40 percent.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Dihydropyridines
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of studies have demonstrated the effectiveness of the dihydropyridines in stable angina [
         <a href="#rid10">
          10-12
         </a>
         ]. In the International Multicenter Angina Exercise (IMAGE) trial, 280 patients with chronic stable angina were randomized to six weeks therapy with long-acting preparations of
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         (20 mg BID) or
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         (200 mg once daily) [
         <a href="#rid10">
          10
         </a>
         ]. Nifedipine reduced the frequency of angina and increased the mean exercise time to 1-mm ST segment depression. However, the increase in exercise time was less than that seen with controlled-release metoprolol (43 versus 70 seconds, p&lt;0.05).
        </p>
        <p>
         In patients already treated with beta blockers and/or nitrates, long-acting
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         has no significant effect on survival. This was demonstrated in the ACTION trial, in which 7665 patients with angina were randomly assigned to long-acting nifedipine 60 mg daily or placebo [
         <a href="#rid13">
          13
         </a>
         ]. At five years, mortality was similar for nifedipine and placebo (1.64 versus 1.53 deaths per 100 patients per year). Nifedipine did significantly reduce the subsequent rates of coronary angiography and bypass surgery. (See
         <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">
          "Goal blood pressure in adults with hypertension"
         </a>
         .)
        </p>
        <p>
         Second generation dihydropyridines (such as
         <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">
          amlodipine
         </a>
         and
         <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">
          nicardipine
         </a>
         ) are also effective antianginal agents. Amlodipine increases exercise duration, decreases the number of anginal attacks, and reduces the consumption of
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         [
         <a href="#rid12">
          12
         </a>
         ]. It is given once daily (at a dose of five or 10 mg) and is well tolerated. Common side effects of the dihydropyridines are less likely with amlodipine [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">
          Nicardipine
         </a>
         , a short-acting dihydropyridine with a side effect profile similar to
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         , has also been shown to be effective in angina. It is remarkably effective in vasospastic (variant) angina [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Reflex tachycardia may limit the effectiveness of
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         and, to a lesser degree, the other dihydropyridines in the treatment of stable angina. This can be overcome by the use of nifedipine in combination with a beta blocker. The effectiveness of nifedipine plus
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         versus either drug alone was compared to placebo in a study of 16 patients with exertional angina [
         <a href="#rid15">
          15
         </a>
         ]. Combination therapy decreased the number of ischemic episodes as determined by ST segment depression on 48 hour ambulatory monitoring when compared to monotherapy or placebo (see
         <a class="local">
          'Combination therapy with beta blockers'
         </a>
         below).
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Dihydropyridines versus verapamil or diltiazem
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several studies have compared the efficacy of
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         to that of
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         and
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         in patients with stable angina. These studies can be summarized as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One report of 32 patients found that exercise time improved from 5.7 minutes with placebo to eight minutes with
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         and up to 10 minutes with
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         [
         <a href="#rid16">
          16
         </a>
         ]. Side effects included a mild bradycardia with verapamil, a mild tachycardia with nifedipine, and angina in four patients taking nifedipine.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another report of 21 patients in a double blind crossover study showed that
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         and
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         appeared to be equally effective in improving exercise time, but fewer patients experienced adverse reactions with diltiazem [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A large study of 551 patients compared
         <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">
          amlodipine
         </a>
         (10 mg daily) and amlodipine (10 mg daily) plus
         <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">
          atenolol
         </a>
         (50 mg daily) to extended-release
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         (480 mg daily given at bedtime) [
         <a href="#rid19">
          19
         </a>
         ]. Compared to placebo, all three strategies improved exercise capacity and there was no difference among them in regard to time to symptoms with exercise, time to ≥1 mm ST segment depression, or number of patients experiencing angina with exercise. However, verapamil and the combination of amlodipine plus atenolol were more effective than amlodipine alone for decreasing myocardial ischemia frequency and duration on ambulatory monitoring, especially in the morning between 6 am and noon.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Verapamil
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          Verapamil
         </a>
         has been shown to increase exercise duration, reduce the number of anginal attacks, and decrease the consumption of
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         tablets in numerous double blind, placebo-controlled randomized trials of patients with chronic stable angina [
         <a href="#rid9">
          9,20-22
         </a>
         ]. The usual effective dose is 360 to 480 mg/day.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          Verapamil
         </a>
         is a safe and effective alternative to beta blockers. Verapamil and
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         are equally effective in preventing anginal attacks and in prolonging exercise duration [
         <a href="#rid23">
          23-26
         </a>
         ]. The choice between the two, therefore, largely depends upon the clinical setting and the side effects of each drug. In recent years, sustained release preparations of verapamil have become available and are as effective as but more convenient than the regular formulation [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Diltiazem
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          Diltiazem
         </a>
         has been shown to reduce anginal frequency,
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         consumption, and increase exercise performance in patients with chronic stable angina in several randomized placebo controlled trials [
         <a href="#rid9">
          9,29-31
         </a>
         ]. The effective antianginal dose is 240 to 360 mg/day. Once and twice daily preparations (such as diltiazem CD) have been found to be as effective as the short-acting form [
         <a href="#rid32">
          32-34
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          Diltiazem
         </a>
         is as effective as beta blockers in the treatment of chronic stable angina. As an example, one study of 33 patients found no difference in efficacy between diltiazem and
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         [
         <a href="#rid35">
          35
         </a>
         ]. Diltiazem is also a safe alternative to beta blockers due to its low incidence of side effects.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Combination therapy with beta blockers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Combination therapy with a calcium channel blocker plus a beta blocker is more effective than therapy with either drug alone.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Verapamil
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          Verapamil
         </a>
         plus a beta blocker may be the most effective combination but it is associated with the highest incidence of significant side effects due to the negative and additive inotropic and chronotropic actions of both drugs [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Nifedipine
         </span>
         <span class="headingEndMark">
          —
         </span>
         The combination of
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         and a beta blocker is associated with fewer side effects than
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         and beta blocker, but is also less efficacious than the combination of beta blockers and other calcium channel blockers [
         <a href="#rid37">
          37
         </a>
         ]. As an example, the IMAGE study described above compared long-acting preparations of nifedipine and
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         , given alone or in combination [
         <a href="#rid10">
          10
         </a>
         ]. Patients received monotherapy for six weeks and combination therapy for another four weeks; exercise testing was performed at both 6 and 10 weeks. The mean increase in exercise time to 1-mm ST segment depression increased with the addition of a second drug (107 versus 37 to 49 seconds with the addition of placebo). However, the anti-ischemic effect from the combination was primarily due to improvement in patients who had not responded to monotherapy rather than to an additive effect of the two drugs. A true additive effect was seen in a minority of patients (14 percent in whom nifedipine was added to metoprolol, and 24 percent in whom metoprolol was added to nifedipine).
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Amlodipine
         </span>
         <span class="headingEndMark">
          —
         </span>
         One study randomized 147 patients with angina and a positive exercise test despite optimal beta blockade to
         <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">
          amlodipine
         </a>
         or placebo [
         <a href="#rid38">
          38
         </a>
         ]. After eight weeks of therapy, there was no difference in time to 1 mm ST segment depression, time to chest pain, or exercise duration, but the number of patients with chest pain during exercise testing was lower with amlodipine than placebo. In the subgroup of patients with early onset of angina (&lt;6 minutes) amlodipine significantly increased the time to chest pain and reduced the amount of ST segment depression and the double product at comparable workloads. There was no difference in the frequency of side effects between the two groups.
        </p>
        <p>
         A second study compared
         <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">
          amlodipine
         </a>
         to
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         in 97 patients with persistent angina despite
         <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">
          atenolol
         </a>
         therapy and found a significant and equivalent reduction in the frequency of anginal episodes with the two agents [
         <a href="#rid39">
          39
         </a>
         ]. However, patients taking diltiazem reported twice as many adverse reactions than those on amlodipine.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Felodipine
         </span>
         <span class="headingEndMark">
          —
         </span>
         The effect of
         <a class="drug drug_general" data-topicid="8438" href="/z/d/drug information/8438.html" rel="external">
          felodipine
         </a>
         along with or instead of a beta blocker was evaluated in 363 patients with angina despite therapy with
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         [
         <a href="#rid40">
          40
         </a>
         ]. The addition of felodipine to metoprolol therapy increased the time to 1 mm ST segment depression and the time to angina during exercise testing and reduced the maximal ST segment depression. In contrast, the exercise test results after replacement of metoprolol with felodipine were not different from those observed during metoprolol therapy.
        </p>
        <p>
         Given these data, the choice of a particular calcium channel blocker-beta blocker combination largely depends upon the clinical setting, the tolerance of side effects, and the severity of ischemic symptoms.
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          ARE CALCIUM CHANNEL BLOCKERS SAFE?
         </span>
         <span class="headingEndMark">
          —
         </span>
         The preceding findings as well as other studies suggested an adverse effect on cardiovascular disease in patients treated with short-acting dihydropyridines and high doses of
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         and
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         (
         <a class="graphic graphic_figure graphicRef51222" href="/z/d/graphic/51222.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid41">
          41-43
         </a>
         ]. In particular, the marked hemodynamic perturbations of large doses of short-acting
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         when given to such vulnerable patients appeared to increase mortality  (
         <a class="graphic graphic_figure graphicRef76385" href="/z/d/graphic/76385.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p>
         These adverse hemodynamic effects are generally not seen when long-acting calcium channel blockers are given to patients with hypertension or stable angina  (
         <a class="graphic graphic_table graphicRef52312" href="/z/d/graphic/52312.html" rel="external">
          table 1
         </a>
         ). The safety of long acting calcium channel blockers, when used for either blood pressure control or relief of angina, was evaluated in a meta-analysis of 15 studies including over 47,000 patients with coronary artery disease [
         <a href="#rid44">
          44
         </a>
         ]. There were no significant differences between the calcium channel blockers and other classes of agents (such as angiotensin converting enzyme inhibitors or beta blockers) or placebo in the rates of all-cause mortality, cardiovascular mortality, nonfatal myocardial infarction, or heart failure. A significant 21 percent relative reduction in the risk of stroke and, as expected, a significant reduction in the risk of angina were noted. No apparent difference was seen between dihydropyridine and nondihydropyridine drugs.
        </p>
        <p>
         The FDA has given the long acting and heart rate lowering calcium channel blockers a "clean bill of health," while warning against short acting
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3832.html" rel="external">
          "Major side effects and safety of calcium channel blockers", section on 'Proposed but unproven serious adverse effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          RECOMMENDATIONS OF OTHERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         We agree with recommendations made by American College of Cardiology Foundation/American Heart Association/American College of Physicians/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society for Cardiovascular Angiography and Interventions/Society of Thoracic Surgeons in their stable ischemic heart disease guideline [
         <a href="#rid46">
          46-48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2684538115">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115939.html" rel="external">
          "Society guideline links: Chronic coronary syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Introduction
         </strong>
         – Beta blockers or nitrates should be used for the initial treatment of chronic coronary syndrome. A calcium channel blocker should be considered if there are contraindications or adverse reactions to either beta blockers or nitrates or if symptoms are not well controlled with a combination of these agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Effectiveness
         </strong>
         –
         <strong>
         </strong>
         All calcium channel blockers are effective in the treatment of chronic coronary syndrome. (See
         <a class="local">
          'Effectiveness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular and adverse side effects
         </strong>
         – The use of short-acting dihydropyridines, such as
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         , is limited by reflex tachycardia which may exacerbate ischemia, thereby preventing its use as monotherapy in this disorder. In addition some studies suggest an increase in mortality when these particular calcium channel blockers are used. (See
         <a class="local">
          'Cardiovascular and adverse side effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Combination therapy
         </strong>
         –
         <strong>
         </strong>
         Therapy with a calcium channel blocker plus a beta blocker is more effective than therapy with either drug alone. We suggest choosing
         <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">
          amlodipine
         </a>
         or
         <a class="drug drug_general" data-topicid="8438" href="/z/d/drug information/8438.html" rel="external">
          felodipine
         </a>
         before other calcium channel blockers, given their better side effect profiles when used in combination with beta blockers. (See
         <a class="local">
          'Combination therapy with beta blockers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vasospastic angina
         </strong>
         – In patients with chronic coronary syndrome, when a vasoactive component to angina is suspected, we suggest a trial of a calcium channel blocker in addition to a beta blocker. (See
         <a class="medical medical_review" href="/z/d/html/1481.html" rel="external">
          "Vasospastic angina", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse side effects
         </strong>
         –
         <strong>
         </strong>
         Calcium channel blockers, particularly
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         and
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         , should be used with caution in patients with left ventricular systolic dysfunction, such as those with an ejection fraction less than 40 percent, or heart failure due to their negative inotropic effect. (See
         <a class="local">
          'Cardiovascular and adverse side effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H71939930">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff thank Dr. Julian M. Aroesty for his contributions as an author to prior versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kohlhardt M, Fleckenstein A. Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 1977; 298:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bayer R, Rodenkirchen R, Kaufmann R, et al. The effects of nifedipine on contraction and monophasic action potential of isolated cat myocardium. Naunyn Schmiedebergs Arch Pharmacol 1977; 301:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaltenbach M, Schulz W, Kober G. Effects of nifedipine after intravenous and intracoronary administration. Am J Cardiol 1979; 44:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henry PD, Shuchleib R, Clark RE, Perez JE. Effect of nifedipine on myocardial ischemia: analysis of collateral flow, pulsatile heat and regional muscle shortening. Am J Cardiol 1979; 44:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kitakaze M, Asanuma H, Takashima S, et al. Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs. Circulation 2000; 101:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casolo GC, Balli E, Poggesi L, Gensini GF. Increase in number of myocardial ischemic episodes following nifedipine administration in two patients. Detection of silent episodes by Holter monitoring and role of heart rate. Chest 1989; 95:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joyal M, Cremer KF, Pieper JA, et al. Systemic, left ventricular and coronary hemodynamic effects of intravenous diltiazem in coronary artery disease. Am J Cardiol 1985; 56:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bache RJ, Dymek DJ. Effect of diltiazem on myocardial blood flow. Circulation 1982; 65:I19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krikler DM. Calcium antagonists for chronic stable angina pectoris. Am J Cardiol 1987; 59:95B.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996; 27:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherman LG, Liang CS. Nifedipine in chronic stable angina: a double-blind placebo-controlled crossover trial. Am J Cardiol 1983; 51:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor SH. Usefulness of amlodipine for angina pectoris. Am J Cardiol 1994; 73:28A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agre K. An overview of the safety and efficacy of nicardipine in clinical trials. Am J Cardiol 1987; 59:31J.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dargie HJ, Lynch PG, Krikler DM, et al. Nifedipine and propranolol: a beneficial drug interaction. Am J Med 1981; 71:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subramanian VB, Bowles MJ, Khurmi NS, et al. Randomized double-blind comparison of verapamil and nifedipine in chronic stable angina. Am J Cardiol 1982; 50:696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace WA, Wellington KL, Murphy GW, Liang CS. Comparison of antianginal efficacies and exercise hemodynamic effects of nifedipine and diltiazem in stable angina pectoris. Am J Cardiol 1989; 63:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klinke WP, Kvill L, Dempsey EE, Grace M. A randomized double-blind comparison of diltiazem and nifedipine in stable angina. J Am Coll Cardiol 1988; 12:1562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frishman WH, Glasser S, Stone P, et al. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 1999; 83:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiner DA, Klein MD. Verapamil therapy for stable exertional angina pectoris. Am J Cardiol 1982; 50:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subramanian VB, Lahiri A, Paramasivan R, Raftery EB. Verapamil in chronic stable angina. A controlled study with computerized multistage treadmill exercise. Lancet 1980; 1:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brodsky SJ, Cutler SS, Weiner DA, et al. Treatment of stable angina of effort with verapamil: a double-blind, placebo-controlled randomized crossover study. Circulation 1982; 66:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pine MB, Citron PD, Bailly DJ, et al. Verapamil versus placebo in relieving stable angina pectoris. Circulation 1982; 65:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frishman WH, Klein NA, Klein P, et al. Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris. A placebo-controlled double-blind randomized crossover trial. Am J Cardiol 1982; 50:1164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subramanian VB, Bowles MJ, Davies AB, Raftery EB. Calcium channel blockade as primary therapy for stable angina pectoris. A double-blind placebo-controlled comparison of verapamil and propranolol. Am J Cardiol 1982; 50:1158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson SM, Mauritson DR, Corbett JR, et al. Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris. Am J Med 1981; 71:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiner DA, Klein MD, Cutler SS. Efficacy of sustained-release verapamil in chronic stable angina pectoris. Am J Cardiol 1987; 59:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cutler NR, Anders RJ, Jhee SS, et al. Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. Am J Cardiol 1995; 75:1102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hossack KF, Pool PE, Steele P, et al. Efficacy of diltiazem in angina on effort: a multicenter trial. Am J Cardiol 1982; 49:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strauss WE, McIntyre KM, Parisi AF, Shapiro W. Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: report of a cooperative clinical trial. Am J Cardiol 1982; 49:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindenberg BS, Weiner DA, McCabe CH, et al. Efficacy and safety of incremental doses of diltiazem for the treatment of stable angina pectoris. J Am Coll Cardiol 1983; 2:1129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiner DA, Cutler SS, Klein MD. Efficacy and safety of sustained-release diltiazem in stable angina pectoris. Am J Cardiol 1986; 57:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nadeau C, Hilton D, Savard D, et al. Three-month efficacy and safety of once-daily diltiazem in chronic stable angina pectoris. Am J Cardiol 1995; 75:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thadani U, Glasser S, Bittar N, Beach CL. Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris. Diltiazem CD Study Group. Am J Cardiol 1994; 74:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Dijk RB, Lie KI, Crijns HJ. Diltiazem in comparison with metoprolol in stable angina pectoris. Eur Heart J 1988; 9:1194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strauss WE, Parisi AF. Superiority of combined diltiazem and propranolol therapy for angina pectoris. Circulation 1985; 71:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leon MB, Rosing DR, Bonow RO, Epstein SE. Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris. Am J Cardiol 1985; 55:69B.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunselman PH, van Kempen LH, Bouwens LH, et al. Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. Am J Cardiol 1998; 81:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knight CJ, Fox KM. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Studies in Angina Research (CESAR) Investigators. Am J Cardiol 1998; 81:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunselman P, Liem AH, Verdel G, et al. Addition of felodipine to metoprolol vs replacement of metoprolol by felodipine in patients with angina pectoris despite adequate beta-blockade. Results of the Felodipine ER and Metoprolol CR in Angina (FEMINA) Study. Working Group on Cardiovascular Research, The Netherlands (WCN). Eur Heart J 1997; 18:1755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92:1326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kloner RA. Nifedipine in ischemic heart disease. Circulation 1995; 92:1074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bangalore S, Parkar S, Messerli FH. Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis. Am J Med 2009; 122:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marwick C. FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA 1996; 275:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:e354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:3097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2014; 64:1929.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1471 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/895901" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/600318" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The effects of nifedipine on contraction and monophasic action potential of isolated cat myocardium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/495489" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Effects of nifedipine after intravenous and intracoronary administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/495487" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Effect of nifedipine on myocardial ischemia: analysis of collateral flow, pulsatile heat and regional muscle shortening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10645928" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2920581" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Increase in number of myocardial ischemic episodes following nifedipine administration in two patients. Detection of silent episodes by Holter monitoring and role of heart rate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4036821" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Systemic, left ventricular and coronary hemodynamic effects of intravenous diltiazem in coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7053295" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Effect of diltiazem on myocardial blood flow.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2880496" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Calcium antagonists for chronic stable angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8557899" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6402914" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Nifedipine in chronic stable angina: a double-blind placebo-controlled crossover trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8310973" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Usefulness of amlodipine for angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15351192" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3300239" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : An overview of the safety and efficacy of nicardipine in clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7025625" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Nifedipine and propranolol: a beneficial drug interaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7124629" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Randomized double-blind comparison of verapamil and nifedipine in chronic stable angina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2492741" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Comparison of antianginal efficacies and exercise hemodynamic effects of nifedipine and diltiazem in stable angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3057036" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A randomized double-blind comparison of diltiazem and nifedipine in stable angina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10073852" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6814225" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Verapamil therapy for stable exertional angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6103208" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Verapamil in chronic stable angina. A controlled study with computerized multistage treadmill exercise.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6807568" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Treatment of stable angina of effort with verapamil: a double-blind, placebo-controlled randomized crossover study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7053279" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Verapamil versus placebo in relieving stable angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6127946" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris. A placebo-controlled double-blind randomized crossover trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6127945" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Calcium channel blockade as primary therapy for stable angina pectoris. A double-blind placebo-controlled comparison of verapamil and propranolol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7282732" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3544792" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Efficacy of sustained-release verapamil in chronic stable angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7762493" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7036710" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Efficacy of diltiazem in angina on effort: a multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7036709" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: report of a cooperative clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6355242" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Efficacy and safety of incremental doses of diltiazem for the treatment of stable angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3510525" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Efficacy and safety of sustained-release diltiazem in stable angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7710563" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Three-month efficacy and safety of once-daily diltiazem in chronic stable angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8017316" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris. Diltiazem CD Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3234411" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Diltiazem in comparison with metoprolol in stable angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3921278" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Superiority of combined diltiazem and propranolol therapy for angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2857518" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9591892" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9591893" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Studies in Angina Research (CESAR) Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9402450" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Addition of felodipine to metoprolol vs replacement of metoprolol by felodipine in patients with angina pectoris despite adequate beta-blockade. Results of the Felodipine ER and Metoprolol CR in Angina (FEMINA) Study. Working Group on Cardiovascular Research, The Netherlands (WCN).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7637142" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The risk of myocardial infarction associated with antihypertensive drug therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7648682" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7648647" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Nifedipine in ischemic heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19332231" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8627948" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23166211" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23166210" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25077860" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
